Secondary Outcome(s)
|
Adapted sJIA ACR 30/50/70/90/100 response at every visit from Day 7 onward in the open label and double blind phase.
[Time Frame: Up to 82 weeks after randomization]
|
Achievement of corticosteroid tapering at the end of the open-label phase
[Time Frame: 12 to 40 weeks]
|
Fever (Temp >38 Degrees Celsius) attributed to sJIA at Day 3, Day 7 and Day 14 of the open label phase.
[Time Frame: Day 3, Day 7, Day 14]
|
Change from baseline in Child Health Questionnaire (CHQ) responses at the end of Part 1 and Part 2 of the open label phase, at randomization and every 3 months thereafter.
[Time Frame: Up to 82 weeks after randomization.]
|
Change from baseline in Juvenile Arthritis Disease Activity Score (JADAS 27) at every visit from Day 7 onward in the open label and double blind phase.
[Time Frame: Up to 82 weeks after randomization.]
|
Change from baseline in Child Health Assessment Questionnaire (CHAQ) at every visit from Day 7 onward in the open label and double blind phase.
[Time Frame: Up to 82 weeks after randomization.]
|
"Absence of fever", defined as absence of fever due to sJIA in the week preceding the assessment at every visit from Day 7 onward in the open label and double blind phase.
[Time Frame: Up to 82 weeks after randomization.]
|
Change from baseline in each JIA ACR core variable at every visit from Day 7 onward in the open label and double blind phase.
[Time Frame: Up to 82 weeks after randomization.]
|
Occurrence of inactive disease status and clinical remission at every visit from Day 7 onward (JIA ACR) in the open label and double blind phase.
[Time Frame: Up to 82 weeks after randomization.]
|
CRP = 10 mg/L at every visit of the open label phase.
[Time Frame: 12 to 40 weeks]
|
Occurrence of inactive disease status and minimal disease activity clinical remission at every visit from Day 7 onward (JADAS 27) in the open label and double blind phase.
[Time Frame: Up to 82 weeks after randomization.]
|
Time to first Adapted JIA ACR 30 response in Part 1 of the open label phase.
[Time Frame: 12 to 40 weeks]
|
Occurrence of disease flare in double-blind phase
[Time Frame: Up to 82 weeks after randomization]
|
Achievement of a corticosteroid dose of 0.2 mg/kg/day or 10 mg/day (whichever is lower) at the end of the open label treatment period
[Time Frame: 12 to 40 weeks]
|